Skip to content

Psychedelic-assisted therapy: all studies

Page 154 of 294: studies 1,531 to 1,540 of 2,939, newest first. Back to the psychedelic-assisted therapy overview

Research

USO TERAPÊUTICO DA PSILOCIBINA: REVISÃO INTEGRATIVA

Revista fisio&terapia October 8, 2025 Maurício Pedro Luciano da Costa, Pedro Bruschi Peiretti, Pedro Vinicius Rodrigues Silveira Silva et al.

A resurgence of scientific and clinical interest in psychedelic-assisted therapies, particularly with Psilocybin, has been observed. This paper presents an integrative literature review aiming to identify the scientific contributions, potential benefits, and limitations of the therapeutic use of psilocybin in mental health. The study followed a rigorous protocol. Searches were conducted in the...

Psicoterapia assistida por cetamina no tratamento da depressão resistente

Revista Eletrônica Acervo Científico October 7, 2025 Tainá Zen Loss, Carolina Radaelli Fucina, Denise Bergamo Schenato et al.

Objetivo: Analisar a evidência clínica e o racional neurobiológico do uso da cetamina assistida por psicoterapia no tratamento da depressão resistente. Revisão bibliográfica: A depressão resistente ao tratamento (DRT) caracteriza-se pela persistência de sintomas depressivos após falha em pelo menos dois tratamentos antidepressivos adequados, associando-se a prejuízos funcionais, sofrimento...

DOI: 10.25248/reac.e21871.2025 (opens in new tab) Palliative care Medical treatment Gynecology Intensive care medicine +1

On psychedelic liberalism and mad trust: towards varieties of willing in extreme experiences

Biosocieties October 4, 2025 Tehseen Noorani

Abstract The vexed ‘psychotomimetic model’ of psychedelics claims to offer insights into both psychedelic experiences and psychosis, by weaving across these sets of experiences. One enduring opposition to the model distinguishes between psychedelic experiences as voluntary or ‘willed’, and psychosis as an affliction to be endured. This opposition is useful for projects seeking to sanitise and...

DOI: 10.1057/s41292-025-00368-z (opens in new tab) Full text (opens in new tab) Opposition politics Phenomenology philosophy Liberalism Undoing +6

Modification of natural tryptamines for the treatment of neuropsychiatric diseases

Journal of Psychopharmacology October 4, 2025 Michael G. Palfreyman, Geoffrey B. Varty, Erik M. Stang et al. 3 citations

The last decade represented a period of unprecedented interest in, and development of, traditional psychedelic substances for the treatment of a variety of neuropsychiatric disorders. While early clinical trials of classical psychedelics, several of the major ones being tryptamines, have demonstrated robust efficacy in patients with minimal adverse effects, many of these molecules have...

DOI: 10.1177/02698811251368362 (opens in new tab) Tryptamines Mechanism biology Neuropharmacology Clinical trial +3

Treatment Expectation is the Strongest Predictor of Willingness to Participate in Psychedelic Clinical Trials

PsyArXiv October 2, 2025 Anna Paige Payton, Josephine R. Flohr, Boris D. Heifets et al. preprint

Background and Aims: Understanding the factors that lead to participation in psychedelic clinical trials is essential for assessing potential biases in enrollment and ensuring the generalizability of findings. Psychedelic treatment is thought to impact personality traits, psychological flexibility, and expectations, however these non-pharmacological variables may also influence the initial...

The Potential of Psychedelics in the Treatment of Eating Disorders

The Handbook of the Neurobiology of Eating Disorders October 1, 2025 Natalie Gukasyan, Samantha Hilbert, Angela S Guarda

Abstract Psychedelic-assisted therapies are emerging as novel treatments of interest for a range of mental health issues, including eating disorders such as anorexia nervosa. Psychedelics, such as LSD and psilocybin, may exert biological and psychological effects pertinent to the pathophysiology of eating disorders. Initial clinical trials are underway to confirm the safety and therapeutic...

Psychedelika assistierte Therapie

Psychotherapie-Wissenschaft October 1, 2025 Heiner Dörfler

Die psychedelika assistierte Psychotherapie erfährt aktuell eine wissenschaftlich fundierte Renaissance. Studien zeigen eine therapeutische Wirksamkeit von Substanzen wie Psilocybin, LSD und MDMA bei verschiedenen psychischen Störungsbildern, insbesondere bei therapieresistenter Depression, PTBS, Angstund Suchterkrankungen. In der Schweiz nimmt diese Entwicklung eine besondere Stellung ein: Als...

DOI: 10.30820/1664-9583-2025-2-7 (opens in new tab) Chronic disease Butyrophenone Continuing education Gynecology

Indole therapeutics: Latest FDA updates, ongoing trials, and future directions.

Drug Discovery Today October 1, 2025 Noor-Ul-Huda Butt, Sultan Nacak Baytas 4 citations

Indole-based compounds serve as versatile pharmacophores across anticancer, antiviral, neurological, antimicrobial, and metabolic therapies. This review systematically analyses FDA-approved, withdrawn, and investigational indole-containing drugs over the past decade, focusing on evolving clinical outcomes, regulatory decisions, and therapeutic repositioning. It explores the shift from cytotoxic...

DOI: 10.1016/j.drudis.2025.104471 (opens in new tab) Full text (opens in new tab) FDA Approvals Cancer Clinical trials Drug development +3

The effect of MDMA administration on oxytocin concentration levels: systematic review and a multilevel meta-analysis in humans.

Neuroscience & Biobehavioral Reviews October 1, 2025 Anna Vaslavski, Anna Harwood Gross, Salomon Israel et al. 1 citation

3,4-Methylenedioxmethamphetamine (MDMA) has been shown to enhance social cognition, partly through its effects on oxytocin, a neuropeptide involved in social cognition. Despite growing evidence linking MDMA to increased oxytocin levels, no study has systematically examined this relationship across different doses, times, and participant characteristics. This systematic review and meta-analysis...

Psychedelics Reverse the Polarity of Long-Term Synaptic Plasticity in Cortical-Projecting Claustrum Neurons

eNeuro October 1, 2025 Tanner L. Anderson, Artin Asadipooya, Pavel I. Ortinski 3 citations

Psychedelic drugs have garnered increasing attention for their therapeutic potential in treating a variety of psychiatric diseases, such as depression, anxiety, and substance use disorder. The claustrum (CLA), a brain area with remarkable interconnectivity to frontal cortices, has recently been shown to have a dense population of serotonin 2 receptors (5-HT2Rs) that are activated by...

DOI: 10.1523/eneuro.0047-25.2025 (opens in new tab) Full text (opens in new tab) Neuroplasticity Excitatory postsynaptic potential Long-term potentiation Claustrum +12